A clinical-stage biotechnology company in Immuno-Oncology and Immuno-Inflammation

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

30/04/2026

Download

T-cell activation through neo-epitopes
Transforming tumor microenvironment
suppressive cells into effector cells

Down regulating T effector cells to decrease immunological reactivity

Up regulating regulatory
T-cells to develop immune tolerance

Three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies

Premier international pharma, clinical and academic collaborations to speed up the delivery of our product candidates to patients in need

To download the documents